News >

FDA Approves Frontline Cabozantinib for Advanced RCC

Silas Inman @silasinman
Published: Tuesday, Dec 19, 2017

Toni K. Choueiri, MD

Toni K. Choueiri, MD
The FDA has approved cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma (RCC), based on a meaningful improvement in progression-free survival (PFS) versus sunitinib (Sutent) in the CABOSUN trial.

= 0.29).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x